Key Takeaways
- Clinical Bottom Line
- Eradicating the Field Defect
Clinical Bottom Line
| Target Pathology | RFA Device Application | Therapeutic Goal |
|---|---|---|
| Barrett’s with Low-Grade Dysplasia | Focal or Circumferential ablation utilizing the Barrx system. | Complete Eradication of Intestinal Metaplasia (CEIM). |
| Barrett’s with High-Grade Dysplasia | Mandatory initial EMR of visible nodules, followed immediately by heavy RFA of all remaining flat Barrett’s. | Eradicating the entire field defect to prevent metachronous (recurrent) cancer. |
Eradicating the Field Defect
When an endoscopist definitively confirms High-Grade Dysplasia (HGD) within a 6cm segment of Barrett’s esophagus, simply removing the single visible nodule via Endoscopic Mucosal Resection (EMR) is completely insufficient. The entire 6cm “field” of abnormal columnar tissue is genetically unstable. Leaving it behind guarantees an aggressive local recurrence.
The Barrx Burn
Radiofrequency Ablation (RFA) serves as the ultimate “clean-up” mechanism. Utilizing a specialized balloon (e.g., Barrx) covered in a dense grid of tightly spaced bipolar electrodes, the system delivers highly concentrated, microsecond bursts of thermal energy. Because the electrodes are microscopically spaced, the depth of the burn is mathematically restricted to the absolute superficial mucosal layer (approximately 1mm deep). This thoroughly disintegrates the pre-malignant Barrett’s cells while intentionally preserving the deep submucosal tissue, entirely avoiding the catastrophic deep stricturing associated with older, uncontrolled thermal therapies like Argon Plasma Coagulation (APC).
Clinical guidelines summarized by the Gastroscholar Research Team. Last updated: 2026. This article is intended for physicians.
